Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses
Open Access
- 1 May 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (9), 3753-3754
- https://doi.org/10.1182/blood-2002-12-3920
Abstract
Acquired factor VIII (FVIII) inhibitors can cause life-threatening bleeding. Rapid restoration of coagulation is vital. Therapeutic approaches include factor substitution,[1][1],[2][2]immunosuppression (eg, steroids, cyclophosphamide[3][3]), and plasmapheresis.[4][4] A novel treatment option isKeywords
This publication has 12 references indexed in Scilit:
- Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophiliaBlood, 2003
- Rituximab in the treatment of acquired factor VIII inhibitorsBlood, 2002
- Treatment of refractory autoimmune (acquired) haemophilia with anti‐cd20 (rituximab)British Journal of Haematology, 2002
- Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletionAnnals Of The Rheumatic Diseases, 2002
- Treating human autoimmune disease by depleting B cellsAnnals Of The Rheumatic Diseases, 2002
- Severe cold hemagglutinin disease (CHD) successfully treated with rituximabBlood, 2002
- Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpuraBlood, 2001
- Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitorAmerican Journal of Hematology, 1989
- Acquired HemophiliaArchives of Internal Medicine, 1987
- Porcine factor VIII and plasmapheresis in the management of hemophiliac patients with inhibitorsAmerican Journal of Hematology, 1986